Wolverine Trading
VNDA icon

Wolverine Trading’s Vanda Pharmaceuticals VNDA Stock Holding History

Wolverine Trading’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,417
Closed -$54.6K – 6238
2025
Q2 		$54.6K Buy
+11,417
New +$49.9K ﹤0.01% 4326
2025
Q1 		– Sell
-10,495
Closed -$48.9K – 5932
2024
Q4 		$50.2K Sell
10,495
-1,622
-13% -$7.79K ﹤0.01% 4985
2024
Q3 		$56.6K Buy
+12,117
New +$65K ﹤0.01% 4515
2024
Q1 		– Sell
-11,101
Closed -$46.8K – 5378
2023
Q4 		$46.8K Buy
+11,101
New +$44.8K ﹤0.01% 4273
2019
Q2 		– Sell
-12,793
Closed -$204K – 5185
2019
Q1 		$235K Buy
+12,793
New +$292K ﹤0.01% 3636
2016
Q3 		– Sell
-14,677
Closed -$198K – 5166
2016
Q2 		$163K Buy
+14,677
New +$142K ﹤0.01% 3408

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Wolverine Trading's VNDA Position: Q3 2025 in Review

Wolverine Trading sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 11,417 shares — an estimated $54.6K sold.

Wolverine Trading first reported a position in VNDA in Q2 2016 and held it in 6 quarters. The position peaked at $235K in Q1 2019. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.

  • Wolverine Trading reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wolverine Trading sold 11,417 Vanda Pharmaceuticals shares in Q3 2025, an estimated $54.6K.
  • Wolverine Trading first reported a position in Vanda Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Wolverine Trading's Vanda Pharmaceuticals position peaked at $235K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.